Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma

Molecular Carcinogenesis

Volumn 54, Issue 9, 2015, Pages 900-907

  Wang, Lisha ^a,b   Williamson, Sean R ^c   Zhang, Shaobo ^b   Huang, Jiaoti ^d   Montironi, Rodolfo ^e   Davison, Darrell D ^b   Wang, Mingsheng ^b   Yao, Jorge L ^f   Lopez Beltran, Antonio ^g   Osunkoya, Adeboye O ^h   Maclennan, Gregory T ⁱ   Baldridge, Lee Ann ^b   Du, Xiang ^a   Cheng, Liang ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f Pathline Laboratories   (United States)

^g UNIVERSITY OF CÓRDOBA   (Spain)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Gene copy number; Molecular cytogenetics, fluorescence in situ hybridization; Prostate; Small cell carcinoma; TMPRSS2 ERG rearrangement; Tumorigenesis

Indexed keywords

ANDROGEN RECEPTOR; TRANSCRIPTION FACTOR ERG; AR PROTEIN, HUMAN; ONCOPROTEIN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; GENE DOSAGE; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84938928755     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22162     Document Type: Article

References (61)

1. Bostwick DG, Cheng L. Urologic surgical pathology. 3rd edition. Philadelphia, PA: Elsevier; 2014.
2. Eble JN, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, Oxford: IARC Press; Oxford University Press (distributor); 2004.
3. Anker CJ, Dechet C, Isaac JC, Akerley W, Shrieve DC. Small-cell carcinoma of the prostate. J Clin Oncol 2008; 26:1168-1171.
4. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987; 59:1803-1809.
5. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 1992; 147:804-807.
6. Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973-2003: A population-based study. BJU Int 2012; 109:824-830.
7. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32:65-71.
8. Spiess PE, Pettaway CA, Vakar-Lopez F, et al. Treatment outcomes of small cell carcinoma of the prostate: A single-center study. Cancer 2007; 110:1729-1737.
9. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24:820-828.
10. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: Evidence supporting monoclonal origin. Mod Pathol 2011; 24:1120-1127.
11. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29:3651-3658.
12. Haapala K, Kuukasjarvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 2007; 38:474-478.
13. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61:3550-3555.
14. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45.
15. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23:1061-1067.
16. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 2009; 56:275-286.
17. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2: ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009; 69:6027-6032.
18. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351:1488-1490.
19. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-8261.
20. Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007; 13:953-957.
21. Marks RA, Zhang S, Montironi R, et al. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis. Prostate 2008; 68:919-923.
22. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9:401-406.
23. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176.
24. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807.
25. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012; 25:1543-1549.
26. Arihiro K, Oda M, Ogawa K, et al. Comparison of evaluations of hormone receptors in breast carcinoma by image-analysis using three automated immunohistochemical stainings. Exp Ther Med 2010; 1:927-932.
27. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487:239-243.
28. Hong H, Kao C, Jeng MH, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004; 101:83-89.
29. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-39.
30. Cheng L, Slezak J, Bergstralh EJ, et al. Dedifferentiation in the metastatic progression of prostate cancer. Cancer 1999; 86:657-663.
31. Yu J, Mani RS, Cao Q, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17:443-454.
32. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2013; [Epub ahead of print].
33. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25:276-308.
34. Visakorpi T, Kallioniemi AH, Syvanen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55:342-347.
35. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815-2825.
36. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56:937-943.
37. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1:487-495.
38. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6:703-706.
39. Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012; 360:3-13.
40. Lorente D, De Bono JS. Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer 2014; 50:753-764.
41. Rodrigues DN, Butler LM, Estelles DL, de Bono JS. Molecular pathology and prostate cancer therapeutics: From biology to bedside. J Pathol 2013; 232:178-184.
42. Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 1: The androgen receptor and steroidogenic pathways. BJU Int 2009; 104:438-448.
43. Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 2: The androgen receptor and 5alpha-reductase. BJU Int 2009; 104:1191-1197.
44. Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011; 47:R25-R41.
45. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22.
46. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-648.
47. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31:882-888.
48. Esgueva R, Perner S, LaFargue JC, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23:539-546.
49. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29:3659-3668.
50. Guo CC, Dancer JY, Wang Y, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011; 42:11-17.
51. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20:538-544.
52. Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: The superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013; 44:2227-2233.
53. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005; 166:1533-1539.
54. Bastus NC, Boyd LK, Mao X, et al. Androgen-induced TMPRSS2: ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70:9544-9548.
55. Mertz KD, Setlur SR, Dhanasekaran SM, et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: A new perspective for an old model. Neoplasia 2007; 9:200-206.
56. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69:2912-2918.
57. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22:1083-1093.
58. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009; 15:3251-3255.
59. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63:920-926.
60. Cheng L, Zhang DY, Eble JN. Molecular genetic pathology. 2nd edition. New York: Springer; 2013.
61. Cheng L, Eble JN. Molecular surgical pathology. 1st edition. New York: Springer; 2013.